| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
John B Bode is Director at ZVRA, with reported holdings spanning 3 companies. John B Bode's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.4M at current prices.
Our model assigns John B Bode a middling insider score of 67/100, based on 5 past trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +37.9%.
John B Bode's largest disclosed position is in ZVRA as Director, worth about $1.3M. Net of sales, the ZVRA filings show accumulation of 45,000 shares.
John B Bode has 11 Form 4 filings on record from May 2023 to September 2026, across 3 companies: Director at SPAR Group (SGRP), 2026; Director at Zevra Therapeutics (ZVRA), 2023–2026; Director at Newton Golf (NWTG), 2026.
The 17 reported transactions were 10 open-market purchases, 3 option or other derivative awards, 2 stock awards and 2 option exercises.
Counted by filing, the open-market trades come to 5 purchases worth about $286K and no sales.
The largest open-market purchase was 10,000 shares of ZVRA at an average $7.96 on March 19, 2025, about $80K. Twelve months later ZVRA was up 18%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 5,000 | $9.17 | $45,825.00 | +12.5% | +1.9% | +34.7% | |
| Mar 19, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $7.96 | $79,624.00 | +33.3% | +10.8% | +18.2% | |
| Jul 12, 2024 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.87 | $58,661.00 | +50.0% | +35.4% | +114.2% | |
| Sep 5, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.13 | $51,333.00 | +100.0% | +0.8% | +42.9% | |
| May 18, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.04 | $50,417.69 | New | +2.8% | -6.3% |